NASDAQ · Financial Statements
NervGen Pharma Corp. (NGEN) Financial Statements
$1.73
NASDAQ: NGEN
Market Cap $142.19M
Overview Financials Dividend NervGen Pharma Corp. most recently reported annual revenue of $0, net profit of $-44.0M. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.
Annual Financials (USD)
Metric 2021 2022 2023 2024 2025 Revenue $0 $0 $0 $0 $0 Operating Profit $-13.0M $-23.0M $-18.0M $-25.0M $-25.0M Net Profit $-13.0M $-21.0M $-22.0M $-24.0M $-44.0M EPS $-0.33 $-0.39 $-0.37 $-0.36 $-0.61 Op Margin — — — — —
Balance Sheet (USD)
Metric 2021 2022 2023 2024 2025 Total Assets $18.0M $24.0M $13.0M $19.0M $23.0M Total Liabilities $1.0M $10.0M $15.0M $17.0M $20.0M Cash $17.0M $22.0M $12.0M $17.0M $22.0M Borrowings $0 $0 $0 $0 $0
Cash Flow (USD)
Metric 2021 2022 2023 2024 2025 Operating Cash Flow $-8.0M $-18.0M $-11.0M $-17.0M $-19.0M Investing Cash Flow $0 $0 $0 $0 $0 Financing Cash Flow $0 $0 $0 $0 $-1.0M Net Cash Flow $11.0M $4.0M $-10.0M $5.0M $5.0M Free Cash Flow $-8.0M $-18.0M $-11.0M $-17.0M $-19.0M
Valuation & Return Ratios
Metric Value PEG Ratio 0.12 EV / EBITDA -15.42 FCF Yield -4.78% Quick Ratio 1.16 Interest Coverage 0.00 Return 1Y -42.57% Return 3Y 32.82% Return 5Y 24.02%
Screens featuring this stock